top
Search terms
Results 1 - 10 of 16 - ordered by :
Pages: 1 2
Ehjournal

The causality of plasma low-density lipoprotein-cholesterol (LDL-C) and reduced LDL receptor-mediated LDL uptake in the pathophysiology of ASCVD has been established beyond any reasonable doubt.3 For ...

European Heart Journal, Landmesser, Ulf, John Chapman, M., Farnier, Michel, Gencer, Baris, Gielen, Stephan, Hovingh, G. Kees, Lüscher, Thomas F., Sinning, David, Tokgözoğlu, Lale, Wiklund, ...

Date : 01/08/2017 Item size : 477757 bytes
Ehjournal

While the former focused on individuals considered healthy, the latter was designed to avoid future events in those who already had coronary artery disease, myocardial infarction, or stroke.1 ...

European Heart Journal, Lüscher, Thomas F.

Date : 14/06/2017 Item size : 223163 bytes
Ehjournal

The causality of plasma low-density lipoprotein-cholesterol (LDL-C) and reduced LDL receptor-mediated LDL uptake in the pathophysiology of ASCVD has been established beyond any reasonable doubt.3 For ...

European Heart Journal, Landmesser, Ulf, John Chapman, M., Farnier, Michel, Gencer, Baris, Gielen, Stephan, Hovingh, G. Kees, Lüscher, Thomas F., Sinning, David, Tokgözoğlu, Lale, Wiklund, ...

Date : 09/03/2017
Ehjournal

The causality of plasma low-density lipoprotein-cholesterol (LDL-C) and reduced LDL receptor-mediated LDL uptake in the pathophysiology of ASCVD has been established beyond any reasonable doubt.3 For ...

European Heart Journal, Landmesser, Ulf, John Chapman, M., Farnier, Michel, Gencer, Baris, Gielen, Stephan, Hovingh, G. Kees, Lüscher, Thomas F., Sinning, David, Tokgözoğlu, Lale, Wiklund, ...

Date : 08/03/2017 Item size : 424498 bytes
Ehjournal

The metabolic syndrome not only precedes cardiovascular conditions, and hence represents an important cluster of risk factors,1,2 but also remains relevant in patients with established coronary ...

European Heart Journal, Lüscher, Thomas F.

Date : 14/10/2015 Item size : 195267 bytes
Ehjournal

The metabolic syndrome not only precedes cardiovascular conditions, and hence represents an important cluster of risk factors,1,2 but also remains relevant in patients with established coronary ...

European Heart Journal, Lüscher, Thomas F.

Date : 14/10/2015 Item size : 205910 bytes
Ehjournal

Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors are a new class of drugs able to decrease LDL-C by 5070% when administered either as a monotherapy or on a background with statins.46 ...

European Heart Journal, Lüscher, Thomas F.

Date : 21/09/2015
Ehjournal

Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors are a new class of drugs able to decrease LDL-C by 5070% when administered either as a monotherapy or on a background with statins.46 ...

European Heart Journal, Lüscher, Thomas F.

Date : 21/09/2015 Item size : 220026 bytes
Ehjournal

Download the Issue @ a Glance podcast Subscribe to the EHJ Podcast Prevention is better that cure As Niccolo Machiavelli already pointed out in his seminal work Il Principe in 1513, any disease is ...

European Heart Journal, Lüscher, Thomas F.

Date : 14/05/2015
Ehjournal

Download the Issue @ a Glance podcast Subscribe to the EHJ Podcast Prevention is better that cure As Niccolo Machiavelli already pointed out in his seminal work Il Principe in 1513, any disease is ...

European Heart Journal, Lüscher, Thomas F.

Date : 14/05/2015 Item size : 183449 bytes